CAM Assay
The chorioallantoic membrane (CAM) assay is a well-established in vivo model for studying angiogenesis (new blood vessel formation) and evaluating the pro- or anti-angiogenic properties of biomaterials, drugs, and bioactive molecules. Developed by Judah Folkman in the 1970s, the assay uses the highly vascularized CAM of developing chick embryos as a platform for implanting test materials and observing vascular response. The CAM provides a transparent, immunologically naive microenvironment with rapid and reproducible neovascularization, making it ideal for screening angiogenic potential and assessing biomaterial biocompatibility.
Source record
Citations copied verbatim from the method’s source record. No claim-level verification is inferred from them.
- Folkman, J. (1974). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186. · URL
- Ribatti, D. (2016). The chick embryo chorioallantoic membrane (CAM) assay. Current Protocols in Immunology, 15, 12.1-12.13. · DOI 10.1016/j.reprotox.2016.11.004
- Norris, C. S., Griffith, O. W., & Reid, L. M. (2003). The chorioallantoic membrane (CAM) as a model for angiogenesis. In Antiangiogenic Agents in Cancer Therapy. Humana Press, pp. 463-477. · URL
Curated claims
Claims persisted in the evidence ledger, each with its own assessment.
This view does not invent a claim assessment when the ledger has none.
Related methods
Generated from the method graph and shown as machine-suggested relations — no evidence claim is inferred.